Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids

Giets den Besten,1,4 Katja Lange,3,4 Rick Havinga,1 Theo H. van Dijk,2 Albert Gerding,2 Karen van Eunen,1,4 Michael Müller,3,4 Albert K. Groen,1,2,4 Guido J. Hooiveld,3,4 Barbara M. Bakker,1,4 and Dirk-Jan Reijngoud1,4

1Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3Nutrition, Metabolism and Genomics Group, Wageningen University, Wageningen, The Netherlands; and 4Netherlands Consortium for Systems Biology, Amsterdam, The Netherlands

Submitted 13 August 2013; accepted in final form 10 October 2013

Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol 305: G900–G910, 2013. First published October 17, 2013; doi:10.1152/ajpgi.00265.2013.—Acetate, propionate, and butyrate are the main short-chain fatty acids (SCFAs) that arise from the fermentation of fibers by the colonic microbiota. While many studies focus on the regulatory role of SCFAs, their quantitative role as a catabolic or anabolic substrate for the host has received relatively little attention. To investigate this aspect, we infused conscious mice with physiological quantities of stable isotopes [1-13C]acetate, [2-13C]propionate, or [2,4-13C2]butyrate directly in the cecum, which is the natural production site in mice, and analyzed their interconversion by the microbiota as well as their metabolism by the host. Cecal interconversion, pointing to microbial cross-feeding, was high between acetate and butyrate, low between butyrate and propionate, and almost absent between acetate and propionate. As much as 62% of infused propionate was used in whole body glucose production, in line with its role as gluconeogenic substrate. Conversely, glucose synthesis from propionate accounted for 69% of total glucose production. The synthesis of palmitate and cholesterol in the liver was high from cecal acetate (2.8 and 0.7%, respectively) and butyrate (2.7 and 0.9%, respectively) as substrates, but low or absent from propionate (0.6 and 0.0%, respectively). Label incorporation due to chain elongation of stearate was approximately eightfold higher than de novo synthesis of stearate. Microarray data suggested that SCFAs exert a mild regulatory effect on the expression of genes involved in hepatic metabolic pathways during the 6-h infusion period. Altogether, gut-derived acetate, propionate, and butyrate play important roles as substrates for glucose, cholesterol, and lipid metabolism.

Address for reprint requests and other correspondence: D.-J. Reijngoud, Hanzeplein 1, 9713 GZ Groningen, The Netherlands (e-mail: D.J.Reijngoud01@umcg.nl).

SCFAs are substrates for energy metabolism in the host (11). The average human diet in Western societies provides 300–600 mmol SCFAs/day, which is equivalent to ~10% of the human caloric daily requirements (3). In the passage from the lumen of the gut to the hepatic vein SCFAs are actively metabolized by colonocytes in the order of butyrate > acetate > propionate (41). The remainder of the SCFAs is largely taken up by the liver (5). Quantitative insight into the partitioning of SCFAs over the subsequent metabolic routes is lacking. According to known biochemical pathways, acetate can be oxidized in the tricarboxylic acid (TCA) cycle or can be used as a substrate for synthesis of cholesterol, ketone bodies, and long-chain fatty acids. Butyrate is supposed to enter mitochondrial fatty acid oxidation and the resulting acetyl-CoA can be used in similar ways as acetate. This leads to the hypothesis that label incorporation from butyrate will resemble that from acetate. Propionate is a well-known precursor for gluconeogenesis in the liver (42), but whether it is used for lipogenesis has not been studied. Detailed analysis of SCFA as substrates was mostly performed in vitro in isolated cell lines derived from colonocytes or hepatocytes, which gives only a limited view on the processes in vivo (2, 7, 10, 33, 41).

The interpretation of available in vivo SCFA studies is complicated by the different administration routes of SCFAs to the host. While the natural production of SCFAs occurs mainly in the cecum, in experiments they are usually administered via food, via intraperitoneal injection, or via intravenous infusion (17, 21, 27, 36). This is likely to affect their impact on energy metabolism via the hormonal and regulatory responses that are triggered in different organs (19, 26).

In this study we present a new mouse model in which we infused conscious mice with stable isotope-labeled SCFAs directly in the cecum at a delivery rate of 2.4 mmol·kg body wt−1·h−1. This infusion rate was estimated to be on the higher side of the physiological range, high enough to ensure substantial isotope enrichment in metabolic end products of SCFAs. To our knowledge, there are no accurate in vivo SCFA production rates published in mice, but there are data from in vitro and in vivo studies in other species. In 12-h-fasted humans the in vivo acetate production was estimated to be 0.75 mmol·kg body wt−1·h−1, whereas it was 1.46 and 1.75 mmol·kg body wt−1·h−1 in 24-h-fasted dogs and 22-h-fasted rats, respectively (36). The total SCFA production was 2.02 mmol·kg body wt−1·h−1 in 22-h-fasted rats (36). It is expected that rates will...
substantially increase particularly in animals fed a fiber-rich diet. By infusing labeled SCFAs at their natural production site at a physiological rate, we get insight into the contributions of biochemical pathways used by the different SCFAs. The results reveal 1) extensive in vivo microbial conversion of SCFAs, compatible with cross-feeding, 2) vivid assimilation of gut-derived SCFAs in host carbohydrates and lipid, and 3) conspicuous differences between the metabolism of the three SCFAs.

MATERIALS AND METHODS

Animals and experimental design. Male C57Bl/6J mice (Charles River, L’Arbresle Cedex, France), 2 mo of age, were housed in a light- and temperature-controlled facility (lights on 6:30 A.M. to 6:30 P.M., 21°C). Mice were fed a semisynthetic diet [based on D12450B (9); Research Diet Services, Wijk Bij Duurstede, The Netherlands] for 6 wk and had free access to drinking water. Experimental procedures were approved by the Ethics Committees for Animal Experiments of the University of Groningen.

Cecal infusion experiment. Mice were equipped with a permanent cecum catheter attached to the skull by acrylic glue under isoflurane anesthesia. Following the surgery, mice were allowed a recovery period of 5 days. Cecal cannulas were flushed daily with phosphate-buffered saline. On the day of the experiment, mice were individually housed and fasted from 6:00 to 10:00 A.M. All infusion experiments were performed in conscious, unrestrained mice. Four different groups received either a control phosphate-buffered saline solution, a 0.3 M sodium [1-13C]acetate (99 atom%; Sigma-Aldrich) solution, a 0.3 M sodium [2-13C]propionate (99 atom%; Sigma-Aldrich) solution, or a 0.3 M sodium [2,4,5-13C]butyrate (99 atom%; Sigma-Aldrich) solution at pH 5.8 infused via the cecum catheter at an infusion rate of 0.2 ml/h. The resulting rate of infusion of labeled SCFA was 2.4 mmol·kg⁻¹·h⁻¹. The infusion rates needed to be high enough to ensure substantial isotope enrichment in metabolic end products of SCFAs. As a consequence, they turned out to be on the higher side of the physiological range. Every hour a blood sample was taken via tail bleeding on filter paper to determine the enrichment in glucose, cholesterol, and acylcarnitines. After 6 h of infusion, animals were killed by cardiac puncture under isoflurane anesthesia. Cecum content and livers were quickly removed, freeze-clamped, and stored at −80°C for fatty acid enrichment determination. Blood was centrifuged (4,000 g for 10 min at 4°C), and plasma was stored at −20°C to determine the enrichment in organic acids and amino acids.

Determination of enrichment and in vivo fluxes. Analytical procedures for extraction of glucose from blood spots, derivatization of the extracted compounds, and GC-MS measurements of derivatives were performed according to van Dijk et al. (50). In brief, glucose was extracted from blood spots using ethanol and converted to its pent-10acetate derivative using pyridine/acetic anhydride (1:2 vol/vol) for 30 min at 60°C. Total cholesterol was extracted from blood spots using ethanol/acetic acid (1:1 vol/vol). Unesterified cholesterol from blood spots was subsequently derivatized using N,O-bis-(trimethyl)silylimidazole with 1% trimethylchlorosilane at room temperature.

Enrichments of SCFAs and plasma organic acids were measured according to Moreau et al. (31) with minor modifications. In short, 100 μl of supernatant were spiked with 100 μl of internal standard (17.3 mM hydroxyisocapronic acid and 20 μl of 20% 5-sulfoisalicylic acid). After a 10-min centrifugation the supernatant was acidified with 10 μl 37% HCl, and SCFA were extracted with 2 ml diethyl ether. Derivatization was performed overnight with 500 μl supernatant and 50 μl of N-trimethylsilylimidazole (N-methyltrifluoroacetic amide). Enrichment of plasma amino acids was determined according to Hušek (22). In brief, plasma was denatured with acetonitrile, and amino acids were derivatized to N-ethoxycarbonyl ethyl esters using ethyl chloroformate at room temperature.

Liver homogenates were prepared in ice-cold phosphate-buffered saline, and different lipid fractions were obtained using thin-layer chromatography as described previously (49). Fatty acids were hydrolyzed in HCl-acetoni trile (1:22 vol/vol) for 45 min at 100°C. Fatty acids were extracted in hexane and derivatized for 15 min at room temperature using Br₂-2,3,4,5,6-pentfluorobenzyl/acetoni triethanol amine (1:6:2 vol/vol). Derivatization was stopped by adding HCl, and the fatty acid-pentafluorobenzyl derivatives were extracted in hexane.

Mass isotopolog distributions were measured using an Agilent 5975 series GC/MSD (Agilent Technologies). Gas chromatography was performed using a ZB-1 column (Phenomenex). Mass spectrometry analysis was performed by electron capture negative ionization using methane as the moderating gas.

The normalized mass isotopolog distributions measured by GC-MS were corrected for natural abundance of 13C by multiple linear regression according to Lee et al. (28) to obtain the excess fractional distribution of mass isotopologs. This distribution was used in mass isotopomer distribution analysis (MIDA) algorithms to calculate acetyl-CoA precursor pool enrichment, fractional palmitate synthesis rates, and the fraction of palmitate and oleate generated by elongation of de novo synthesized palmitate or by elongation of preexisting palmitate as described by Oosterveer et al. (35). The precursor pool enrichment is defined as the enrichment of the biosynthetic precursor subunits for newly synthesized polymers and the fractional synthesis as the fraction of polymer molecules in a mixture that were newly synthesized during the isotopic experiment (20).

Microarray analysis. High-quality total RNA was isolated using TRIzol reagent (Invitrogen) followed by DNase treatment and RNA column purification using the RNAeasy Mini Kit (Qiagen). Quality of all RNA samples was assessed with 6,000 Nano Chips using a bioanalyzer (Agilent Technologies) according to the manufacturer’s instructions. Samples that showed an RNA integrity number above 8.0 were considered of suitable quality for pooled array hybridization. To this end, 3-μg RNA samples of each of the four to six mice per experimental group were pooled. Pooled total RNA (100 ng) was used for whole transcript cDNA synthesis using the Ambion WT expression kit (441974; Applied Biosystems/Life Technologies), and subsequently labeled using the Affymetrix GeneChip WT Terminal Labeling Kit (901524; Affymetrix). Labeled RNA samples (5.5 μg) were hybridized on Mouse Gene 1.1 ST arrays (Affymetrix) and scanned in an Affymetrix GeneTitan instrument. Various advanced quality metrics, diagnostic plots, pseudomages, and classification methods were used to determine the quality of the arrays before analysis (30). Probes were redefined using current genome information (8). In this study probes were reorganized based on the gene definitions as available in the Entrez Gene database, version 38.1. Normalized expression estimates were obtained from the raw intensity values using the robust multitarray analysis preprocessing algorithm available in the library AffyPLM using default settings (23). Gene expression changes were calculated as ratios between SCFA infusions and the control group. Metabolic pathways and genes were retrieved from the KEGG database. Array data are available at the Gene Expression Omnibus under accession no. GSE45926.

Statistics. All data are presented as mean values ± SE. Statistical analysis was assessed by one-way ANOVA using the Tukey test for post hoc analysis. Statistical significance was reached at a P value below 0.05.

RESULTS

In vivo cecal infusion of SCFAs in conscious mice. We developed a new method to infuse conscious mice directly in the cecum with stable SCFA isotope. When the cannula was inserted directly in the cecum, no peristaltic malfunction occurred, in contrast to what was observed when the cannula was inserted in the cecum via the small intestine or colon (unpub-
lished observations). Animals regained presurgery weight after 3 days. Cecal cannulas were flushed daily to prevent obstruction. Infusion rates of 0.2 ml/h did not cause discomfort to the mice, and no back flush in the small intestine or flushing of the colon was observed (observations using carmine). Labeled SCFAs were infused at a concentration of 0.3 M, resulting in a delivery rate of \( \text{\~{}} \text{2.4 mmol·kg}^{-1} \cdot \text{h}^{-1} \), depending on the exact body weight. This ensured substantial isotope enrichment in the metabolic intermediates after 6 h.

**SCFAs are interconverted by gut microbiota.** To investigate bacterial SCFA interconversion in the cecum, the enrichments of cecal SCFAs were measured after a 6-h infusion. Approximately 80–100% of SCFA in the cecum was replaced by the infused isotope (Fig. 1A). Infusion of \([1-13\text{C}]\)acetate resulted in single \( (M^1) \)- and double \( (M^2) \)-labeled butyrate, indicating dimerization of either one labeled acetate and one nonlabeled endogenous acetate or two labeled acetates, respectively. Hardly any label from \([1-13\text{C}]\)acetate was found in propionate (Fig. 1A). Infusion of \([2-13\text{C}]\)propionate gave double-labeled butyrate but no single labeled, suggesting that two labeled propionate molecules were used to synthesize one molecule of double-labeled butyrate. The label enrichment in butyrate produced from propionate was approximately threefold lower compared with butyrate synthesized from acetate (23.3 ± 4.7 and 61.8 ± 4.1%, respectively). Hardly any label from \([2-13\text{C}]\)propionate was found in acetate (Fig. 1A). When \([2,4-13\text{C}_2] \text{butyrate} \) was infused, single-labeled acetate and propionate were found in the cecum (12.3 ± 3.0 and 22.5 ± 4.5%, respectively), showing that gut microbiota convert butyrate into acetate and propionate (Fig. 1A). Overall, these results indicate that there is a high interconversion from acetate to butyrate, a low interconversion from butyrate to acetate and between butyrate and propionate, and almost no interconversion between acetate and propionate (Fig. 1D).

**SCFAs are taken up by the host and transported into the bloodstream.** To assess to which extent gut-derived SCFAs are taken up by the host and reach organs beyond the gastrointestinal tract, we measured the isotopic enrichment of SCFAs in the plasma of the mice (Fig. 1B). The infused \([1-13\text{C}]\)acetate was diluted ninefold in the plasma compared with the cecum.
(9.2 ± 1.2), whereas the infused [2-13C]propionate was only slightly diluted between cecum and blood (1.4 ± 0.1; Fig. 1C). The infused [2,4-13C2]butyrate was diluted approximately two-fold from cecum to blood (2.1 ± 0.2). The high label dilution for acetate indicates a high endogenous acetate metabolism by the host.

**Contribution of SCFAs to glucose.** Propionate can be converted into succinate, which can subsequently support gluconeogenesis via oxaloacetate. Acetate and butyrate enter the TCA cycle as acetyl-CoA and are converted to citrate, followed by the conversion to succinate and finally oxaloacetate (Fig. 5D). Because two carbon atoms are lost in the conversion of citrate into succinate, no net carbon transfer takes place during label transfer from acetate and butyrate to glucose. The carbon atoms lost, however, come from the oxaloacetate moiety in citrate, and, as a consequence, label can be transferred from acetate and butyrate to oxaloacetate, which ends up in triose phosphate and subsequently in glucose.

To investigate label incorporation into glucose, we measured the enrichment in plasma glucose over time during the infusion period and determined the glucose precursor pool enrichment and the fractional glucose flux to the plasma glucose pool by applying MIDA. The glucose precursor pool enrichment is defined as the label enrichment of the biosynthetic precursor subunits (i.e., triose phosphate) that give rise to newly synthesized glucose. It is derived computationally from the ratio of M1 and M2 glucose, assuming that glucose is a dimer of triose phosphate and that the dimerization can be described by a frequency distribution (50). This assumption allows for the calculation of the fractional glucose flux to the total pool of glucose in the compartment of interest (plasma in this case) that has been synthesized from labeled triose phosphate during the infusion experiment (20, 34, 50). Label from the infused SCFAs appeared in glucose already after 1 h infusion and reached isotopic steady state after 4 h of infusion (Fig. 2A). During [1-13C]acetate infusion the steady-state glucose enrichment was 2.0 ± 0.1 and 0.1 ± 0.01% for M1 and M2, respectively. The [2-13C]propionate infusion resulted in an enrichment of 19 ± 1.1 and 3 ± 0.4% for M1 and M2, respectively, at steady state. The infusion of [2,4-13C2]butyrate resulted in a higher glucose enrichment compared with acetate, 11 ± 0.7 and 2 ± 0.3% for M1 and M2, respectively. The calculated enrichment of the triose phosphate precursor pool increased from acetate to propionate to butyrate as substrates (2.8 ± 0.5, 17.6 ± 1.5, and 25.9 ± 0.9%, respectively; Fig. 2B). Irrespective of the pronounced differences in enrichment of the triose phosphate precursor pool during acetate and butyrate infusions, the fractional glucose flux to the total plasma pool of glucose was very similar for acetate and butyrate (39.0 ± 5.4 and 34.0 ± 1.4%, respectively), but almost half of what had been observed with propionate as the substrate (69.1 ± 2.4%; Fig. 2C).

**Incorporation of SCFAs into fatty acids.** To assess hepatic synthesis of different fatty acids from SCFAs we determined hepatic enrichment of palmitate (C16:0) and stearate (C18:0) in four different lipid classes: cholestereyles (CE), free fatty acids (FFA), triglycerides (TG), and phospholipids (PL). All three SCFA infusions resulted in label incorporation into palmitic acid in all four lipid classes. Similar to glucose, MIDA algorithms applied to fatty acids in these lipid classes allows for the calculation of the precursor pool enrichment defined as the enrichment of the biosynthetic precursor subunits for newly synthesized fatty acids. The fractional glucose flux to the plasma pool of fatty acids was 42.0 ± 4.3% for acetate, 4.4 ± 0.2% for propionate, and 22.6 ± 2.1% for butyrate (Fig. 2C).

![Figure 2](http://ajpgi.physiology.org/)

Fig. 2. A: M1 and M2 enrichments of plasma glucose during a 6-h cecal infusion with [1-13C]acetate, [2-13C]propionate, or [2,4-13C2]butyrate. Steady-state glucose precursor pool enrichments (B) and fractional contribution to glucose flux for acetate, propionate, and butyrate (C). Data represent means ± SE for n = 6–7. ***P < 0.001.
synthesized fatty acids (i.e., acetyl-CoA) and the fractional fatty acid synthesis as the fraction of the pool of fatty acids that was newly synthesized during the infusion experiment (20, 34, 50). The precursor enrichment was calculated from the ratio of $M^{+1}$ and $M^{+3}$ palmitate (34, 35). The acetyl-CoA precursor pool enrichments for palmitate and stearate decreased in the order of butyrate > acetate > propionate as substrates (Fig. 3A). FFA and the fatty acyl residues in TG and PL showed comparable precursor enrichments, whereas the precursor enrichment of the fatty acyl residues in CE was approximately two times lower. $[1-^{13}C]$acetate and $[2,4-^{13}C_2]$butyrate resulted in a similar palmitate fractional synthesis in all lipid classes studied ($2.8 \pm 0.2$ and $2.7 \pm 0.4\%$, respectively), whereas $[2-^{13}C]$propionate supported a significantly lower lipid fractional synthesis ($0.6 \pm 0.1\%$; Fig. 3B).

Stearate can either originate from de novo synthesized palmitate or from chain elongation of preexisting palmitate (35). Fractional stearate synthesis from de novo synthesized palmitate was comparable in the four lipid classes (Fig. 3C), but lower than the fractional palmitate synthesis (Fig. 3B). In addition, no de novo stearate synthesis was observed from $[2-^{13}C]$propionate. Chain elongation of preexisting palmitate was comparable for acetate and butyrate ($7.8 \pm 1.0$ and $8.6 \pm 1.3\%$, respectively) but not detectable for propionate as substrate (Fig. 3D). Fractional synthesis by chain elongation of preexisting palmitate decreased in the order of PL > FFA > TG > CE. In addition, chain elongation was significantly higher than de novo stearate synthesis and palmitate synthesis (Fig. 3, B–D).

Acylcarnitines in plasma are used as a proxy of mitochondrial fatty acid oxidation. Changes in the composition of the acylcarnitines in plasma are considered to reflect changes in functioning of the mitochondrial fatty acid oxidation. Accordingly, defects in fatty acid oxidation can be detected by characteristic changes in the acylcarnitine profile. Because the MIDA algorithms applied to the label incorporation into palmitic acid allowed us to calculate the enrichment of the hepatic acetyl-CoA pool, we wondered how these values compared with the enrichment of plasma acetylcarnitine. The measured enrichment of plasma acetylcarnitine was, however, approximately one-third of the average acetyl-CoA precursor enrichment calculated from the label incorporation into the

Fig. 3. A: hepatic precursor pool enrichments in cholesterylester (CE)-derived, triglyceride (TG)-derived, free fatty acid (FFA)-derived, and phospholipid (PL)-derived palmitate after a 6-h cecal infusion with $[1-^{13}C]$acetate, $[2-^{13}C]$propionate, or $[2,4-^{13}C_2]$butyrate. B: hepatic fractional synthesis rates of CE-derived, TG-derived, FFA-derived, and PL-derived palmitate (C16:0) from de novo lipogenesis. Fractional stearate (C18:0) synthesis from elongation of de novo synthesized palmitate (C) and preexisting palmitate (D). M+1 enrichment of acetylcarnitine (E) and palmitoylcarnitine (F) during infusion period. Data represent means ± SE for n = 6–7. *P < 0.05, **P < 0.01, and ***P < 0.001.
palmitoyl residue in TG, FFA, and PL lipid fractions (2.1 ± 0.3 and 6.5 ± 1.6%, respectively; Fig. 3, A and E). It was, however, similar to the precursor enrichment of the CE lipid fraction. Furthermore, the enrichment of acetyl carnitine in plasma showed the same order of decrease as the average of the acetyl-CoA precursor pool enrichments calculated from the label incorporation into the palmitoyl residue in TG, FFA, and PL lipid fractions (butyrate > acetate > propionate). Next, we asked ourselves the question whether newly synthesized palmitate appears in plasma palmitoylcarnitine. As is clear from Fig. 3F labeled palmitoylcarnitine did appear in plasma. After 2 h of infusion the steady-state isotope enrichment was reached for the palmitoylcarnitine (Fig. 3F). Similar to the label efficiency observed in the palmitate residue in the four lipid classes, label incorporation decreased in the order of butyrate > acetate > propionate. At steady state, enrichment of palmitoylcarnitine was one-third of the average palmitate enrichment in FFA, TG, and PL (0.3 ± 0.1 and 1.0 ± 0.1%, respectively). Apparently, lipogenesis influences the composition of acylcarnitines in plasma as does mitochondrial fatty acid oxidation.

**Cholesterol is synthesized from acetate and butyrate but not from propionate.** Because cholesterol synthesis also starts from acetyl-CoA we looked into the incorporation of labeled SCFAs into cholesterol. Incorporation of labeled acetate and butyrate into cholesterol was observed after 1 h of infusion and reached isotopic steady state at 4 h of infusion (Fig. 4A). At steady state, cholesterol enrichment was 0.25 ± 0.03 and 0.08 ± 0.01% for M$^1$ and M$^3$, respectively, during infusion of [1-13C]acetate. During [2,4-13C$_2$]butyrate infusion steady-state enrichment was 0.28 ± 0.03 and 0.10 ± 0.03% for M$^1$ and M$^3$, respectively. The infusion with [2-13C]propionate did not result in any significant enrichment of cholesterol, indicating that propionate is not used as a precursor for cholesterol synthesis. The cholesterol precursor pool enrichment was higher for butyrate compared with acetate as substrate (16.1 ± 1.4 and 9.4 ± 0.8%, respectively; Fig. 4B). The fractional synthesis for cholesterol was equal for acetate and butyrate as substrates (0.7 ± 0.1 and 0.9 ± 0.2%, respectively) and approximately similar to the fractional palmitate synthesis of CE (1.2 ± 0.2 and 1.2 ± 0.5%, respectively), suggesting that the turnover of fatty acyl residues in the CE pool is determined by the cholesteryl residue exchange with free cholesterol (Figs. 3B and 4C).

**SCFAs are incorporated into plasma intermediates of central carbon metabolism.** To determine the role of SCFAs as substrates in whole body energy metabolism we assessed the incorporation of labeled SCFAs into plasma intermediates of central carbon metabolism. Because all organs secrete metabolites into the plasma compartment, the enrichment in plasma metabolites reflects cumulative SCFA metabolism by different organs. For the three-carbon intermediates, pyruvate, lactate, and alanine, enrichment was highest for propionate as a substrate followed by butyrate and acetate (Fig. 5A). Also the three consecutive four-carbon intermediates of the TCA cycle, succinate, fumarate, and malate, and the amino acids aspartate and asparagine derived from oxaloacetate showed incorporation of label from SCFAs (Fig. 5B and D). The enrichment decreased in the order of butyrate > propionate > acetate as substrates. Surprisingly, enrichment increased from succinate to fumarate and malate, which is opposite to the direction of the oxidative flux through the TCA cycle. Infusion of double-labeled butyrate resulted in single- and double-labeled intermediates. Finally, the enrichments in the five-carbon amino acids glutamate and glutamine, which are produced from α-ketoglutarate,
were similar to that of the four-carbon compounds (Fig. 5C).
Again, the enrichment decreased in the order of butyrate > propionate > acetate as substrates, and butyrate infusion resulted in single- and double-labeled metabolites.

Hepatic SCFA fluxes are mainly regulated at the metabolic level. To assess whether the fluxes of SCFAs into glucose, lipids, cholesterol, and central carbon intermediates induced changes in expression of genes encoding metabolic enzymes, we performed a microarray analysis on liver samples after 6 h of infusion. With some small exceptions, all three SCFAs had only minor effects on the expression of genes encoding enzymes involved in glucose metabolism, fatty acid metabolism, cholesterol metabolism, and central carbon metabolism (Fig. 6). Note that the scale in Fig. 6 only ranges from the 2log ratio of \(-0.6\) to 0.6 corresponding to a 1.5 times down- or upregulation, respectively; and therefore all observed changes are minor. The observed changes did not occur in enzymes known to control these metabolic pathways. In agreement, there was no clear induction or reduction of one of the pathways after SCFA infusion. Although we analyzed pooled samples, a principal component analysis (data not shown) revealed a distinction between all three SCFA infusions. Acetate and propionate infusions, however, were more clustered together than butyrate infusion, underlining the distinct metabolic and regulatory role of the three SCFAs. Altogether, these data indicate that the observed conversion of SCFAs into glucose and lipids after 6 h of infusion was mainly regulated at the metabolic level, i.e., by supply of the substrate rather than by changes in gene expression.

**DISCUSSION**

This study presents a comprehensive and quantitative in vivo analysis of partitioning of SCFAs over the different metabolic
routes in the host’s carbohydrate and lipid metabolism, starting from their natural site of production. By infusing stable isotope-labeled SCFAs in physiological quantities directly in the cecum, we quantified bacterial interconversion of SCFAs in the cecum and assimilation of SCFAs in host metabolites. The interconversion of SCFAs in the cecum implies extensive cross-feeding among gut microbiota. The SCFAs that are transported from the lumen of the gut into the host are substrates for central carbon, glucose, fatty acid, and cholesterol metabolism. We confirm the hypothesis that there is a distinct host metabolism of propionate on the one hand and acetate and butyrate on the other hand. More surprisingly, acetate and butyrate incorporation into glucose differs from each other, as we discuss below.

In our study we infused equal amounts of all three SCFAs separately in the cecum. Although this allowed us to study the effects of each SCFA individually, we should note that in our model under physiological conditions SCFAs are present in the cecum in a mixture of 33.3/11006 3.2, 4.5/11006 0.4, and 3.6/11006 0.5 mM for acetate, propionate, and butyrate, respectively. However, various nutritional conditions (i.e., dietary fibers with unique physiochemical properties) elicit different SCFA profiles (11). In our study, the infused SCFA species was always dominant, and this is likely to affect the competition between SCFA for absorption and distribution.

Fig. 6. Heat map of hepatic genes present in the metabolic gene sets derived from the KEGG database after 6 h of infusion with [1-13C]acetate, [2-13C]propionate, or [2,4-13C2]butyrate. Genes are grouped per pathway and can be present in multiple pathways. Data are presented as 3log([mRNA]SCFA infusion/[mRNA]control). The intensity of the red and green color indicates the degree of induction or suppression of a gene, respectively, and ranged from −0.60 (green, downregulation) to 0.60 (red, upregulation). A, acetate; P, propionate; B, butyrate.
interconversion. Future quantitative studies should take this into account.

This study and others showed cross-feeding between acetate-producing and butyrate-producing bacteria (15, 44). The gut microbiota consists of a large community of different bacteria that is stabilized by such mutual cross-feeding (16). We also observed bacterial interconversion between propionate and butyrate, but not between propionate and acetate. Infusing single-labeled propionate resulted in double-labeled butyrate, indicating that species in the gut microbiome produce butyrate from two molecules of propionate with concomitant loss of two carbon atoms. Tholozan et al. (48) showed that butyrate could be formed from a single molecule of propionate by direct carboxylation, but they found no evidence for a dimerization reaction. From the relative frequencies of single- and double-labeled butyrate during propionate infusion, we calculated the enrichment of the monomeric precursor pool leading to butyrate, based on MIDA algorithms (20). This precursor pool was 96.5 ± 3.9% enriched, hence almost identical to the measured cecal propionate enrichment (98.1 ± 1.1%) during [2-13C]propionate infusion. Because no label appeared in acetate during [2-13C]propionate infusion, we conclude that cecal acetate should be released from the liver. If we explain the oxidation of acetate in the liver proceeds at a slower rate than metabolism by the host. Indeed, it has been shown that the label dilution for acetate indicates a high endogenous acetate production (46); thus, a considerable quantity of unlabeled acetate is imported into mitochondria to be converted into labeled oxaloacetate in the TCA cycle. In contrast, butyric-CoA delivers acetyl-CoA to the TCA cycle, all of which takes place in mitochondria.

We analyzed label incorporation into plasma glucose quantitatively by MIDA algorithms. This allowed us to estimate 1) the extent of label incorporation into the triose phosphate precursor pool and 2) the fractional contribution of labeled SCFAs to plasma glucose, independent of the precursor pool enrichment. Incorporation of label from butyrate into triose phosphate was higher than incorporation from the other SCFAs. Labeling of triose phosphate by acetate was only 10% of that observed during [13C]butyrate infusion. This raises questions about the metabolic pathway by which label derived from acetate gets incorporated into triose phosphate. In the host, labeled acetate can be converted by acetyl-CoA synthetase into labeled acetyl-CoA in the cytosol. Acetyl-CoA must then be imported into mitochondria to be converted into labeled oxaloacetate in the TCA cycle. In contrast, β-oxidation of butyrate delivers acetyl-CoA to the TCA cycle, all of which takes place in mitochondria.

Next, we evaluated the fractional contribution of labeled SCFAs to the plasma glucose flux. Only for propionate this

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp2e1</td>
<td>1.0 ± 0.1</td>
<td>1.1 ± 0.1</td>
<td>0.8 ± 0.1</td>
<td>1.0 ± 0.1</td>
</tr>
<tr>
<td>Scl16a1</td>
<td>1.0 ± 0.2</td>
<td>1.2 ± 0.1</td>
<td>1.3 ± 0.1</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>PC</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.2</td>
<td>0.8 ± 0.2</td>
<td>0.8 ± 0.2</td>
</tr>
</tbody>
</table>

Values are means ± SE. Cyp2e1, cytochrome P-450 2E1; Scl16a1, solute carrier family 16, member 1; PC, pyruvate carboxylase.

Table 1. Hepatic mRNA expression in the acetone pathway from fatty acids to Cyp2e1 via 13C2-Butyrate Infusion
butyrate enter the TCA cycle as acetyl-CoA and propionate as from succinate to fumarate and malate. Because acetate and SCFA metabolism. Surprisingly, for all three SCFAs the enrichment of the central carbon metabolism in plasma as a reflection of whole body fatty acids, we also measured enrichments in intermediates of butyrate and not so much via de novo synthesis. In agreement with earlier observations label incorporation into plasma acetylcarnitine and palmitoylcarnitine, stearate from PL compared with TG and FFA was also observed. Also stearate was only labeled by acetate and butyrate, and not propionate to palmityl-CoA, we would expect that the enrichment would decrease from succinate to malate. The lower enrichments in succinate and fumarate indicates an influx of unlabeled metabolites into the plasma compartment from other (not labeled) organs.

Next to the role of SCFAs as substrates, we also assessed whether they might induce gene expression by performing a microarray analysis on liver after 6 h infusion. The small changes in expression of genes involved in metabolic pathways indicate that SCFAs play only a minor role in the regulation of the hepatic gene expression at this time scale. Hence, the observed SCFA metabolism can be attributed largely to preexisting enzymes.

In conclusion, we developed a mouse model in which we infused SCFAs directly in the cecum and showed that there is considerable microbial interconversion between acetate and butyrate as well as between propionate and butyrate. Cecal acetate and butyrate are important substrates for mammalian lipid metabolism, whereas propionate strongly contributes to gluconeogenesis. Furthermore, mitochondrial metabolism of acetate appears to be minimal, in contrast to butyrate. These aspects are key if we aim to understand their strong effects on mammalian carbon and energy metabolism, next to their known role as ligands and regulators.

GRANTS

This work was funded by the Netherlands Genomics Initiative via the Netherlands Consortium for Systems Biology.

DISCLOSURES

The authors declare no conflicts of interest, financial or otherwise, associated with this work.

AUTHOR CONTRIBUTIONS


REFERENCES

G910

HOST METABOLISM OF GUT-DERIVED SHORT-CHAIN FATTY ACIDS


